PALI

Palisade Bio, Inc.

Price Chart

Latest Quote

$1.84

-0.03 (-1.60%)

Current Price

Previous Close	$1.87
Open	$1.90
Day High	$1.97
Day Low	$1.82
Volume	1,940,088

Fetched: 2026-06-23T04:27:26

Stock Information

Shares Outstanding	173.58M
Cash Equivalents	$132.63M
Net Income	$-24.15M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$319.75M
P/E Ratio	15.33
EPS (TTM)	$0.12
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$186.76M
Income	$-24.15M
Book/sh	$0.76
Cash/sh	$0.76
Employees	14

Financial Ratios

Quick Ratio	23.60
Current Ratio	23.71

Returns & Margins

ROA	-23.40%
ROE	-36.40%

Ownership

Insider Ownership	1.64%
Institutional Ownership	93.85%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-7.83
P/B	2.42

Analyst Data

Recommendation	none
Target Price	$9.71

Technical Indicators

SMA20	$1.86
SMA50	$1.97
SMA200	$1.78
RSI	37.76
ATR	0.1479

Shares Float	132.08M
Short Float	17.75%
Short Ratio	11.56
Volatility	1.53
Rel Volume	0.78

Performance History

Week	+7.60%
Month	-2.13%
Quarter	-2.65%
6 Months	+9.52%
YTD	-26.40%
Year	+187.50%
3 Years	-92.43%
5 Years	-99.94%
10 Years	-100.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$1.84	2,088,100
2026-06-18	$1.87	4,040,400
2026-06-17	$1.76	3,952,300
2026-06-16	$1.78	3,491,900
2026-06-15	$1.69	2,109,900
2026-06-12	$1.71	2,181,700
2026-06-11	$1.78	3,094,000
2026-06-10	$1.68	1,359,800
2026-06-09	$1.69	1,704,400
2026-06-08	$1.74	1,100,800
2026-06-05	$1.74	4,319,500
2026-06-04	$1.93	1,526,600
2026-06-03	$1.93	3,392,400
2026-06-02	$1.86	5,199,200
2026-06-01	$2.08	3,372,400
2026-05-29	$2.12	751,900
2026-05-28	$2.06	1,342,400
2026-05-27	$2.07	2,954,000
2026-05-26	$1.99	2,578,100

About Palisade Bio, Inc.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

📰 Latest News

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Motley Fool • 2026-05-21T21:51:11Z

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

Motley Fool • 2026-05-21T21:39:19Z

Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M

Insider Monkey • 2026-05-18T04:49:51Z

We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn

Simply Wall St. • 2026-05-15T11:00:19Z

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile

Insider Monkey • 2026-04-17T13:57:34Z

TSX Penny Stocks To Watch In March 2026

Simply Wall St. • 2026-03-31T19:05:32Z

Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease

MT Newswires • 2026-03-31T18:50:04Z

Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals

MarketBeat • 2026-03-31T18:35:55Z

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

Motley Fool • 2026-03-22T20:26:16Z

Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients

Insider Monkey • 2026-03-18T21:31:56Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$250,000	$0
Operating Revenue	$0	$0	$250,000	$0
Expenses
Interest Expense	$10,000	$12,000	$15,000	$13,000
Total Expenses	$18,056,000	$14,859,000	$13,095,000	$15,311,000
Other Income Expense	$1,285,000	$433,000	$560,000	$1,064,000
Other Non Operating Income Expenses	$1,285,000	$433,000	$785,000	$2,584,000
Net Non Operating Interest Income Expense	$-10,000	$-12,000	$-15,000	$-13,000
Interest Expense Non Operating	$10,000	$12,000	$15,000	$13,000
Operating Expense	$18,056,000	$14,859,000	$13,095,000	$15,311,000
General And Administrative Expense	$7,864,000	$5,796,000	$6,202,000	$8,764,000
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Net Interest Income	$-10,000	$-12,000	$-15,000	$-13,000
Normalized Income	$-16,781,000	$-14,438,000	$-12,075,000	$-12,740,000
Net Income From Continuing And Discontinued Operation	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Total Operating Income As Reported	$-18,056,000	$-14,859,000	$-13,070,000	$-15,721,000
Net Income Common Stockholders	$-16,781,000	$-14,438,000	$-12,316,000	$-14,548,000
Net Income	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Net Income Including Noncontrolling Interests	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Net Income Continuous Operations	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Pretax Income	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Operating Income	$-18,056,000	$-14,859,000	$-12,845,000	$-15,311,000
Special Income Charges	-	$0	$-225,000	$-410,000
Average Dilution Earnings	-	-	-	$0
Per Share
Diluted EPS	$-0.30	$-10.19	$-27.01	$-247.95
Basic EPS	$-0.30	$-10.19	$-27.01	$-247.95
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-16,768,000	$-14,423,000	$-12,056,000	$-12,724,000
Reconciled Depreciation	$3,000	$3,000	$4,000	$3,000
EBITDA (Bullshit earnings)	$-16,768,000	$-14,423,000	$-12,281,000	$-14,244,000
EBIT	$-16,771,000	$-14,426,000	$-12,285,000	$-14,247,000
Diluted Average Shares	$55,669,821	$1,416,471	$456,014	$58,687
Basic Average Shares	$55,669,821	$1,416,471	$456,014	$58,687
Diluted NI Availto Com Stockholders	$-16,781,000	$-14,438,000	$-12,316,000	$-14,548,000
Research And Development	$10,192,000	$9,063,000	$6,893,000	$6,547,000
Selling General And Administration	$7,864,000	$5,796,000	$6,202,000	$8,764,000
Other Gand A	$7,864,000	$5,796,000	$6,202,000	$8,764,000
Total Unusual Items	-	$0	$-225,000	$-1,520,000
Total Unusual Items Excluding Goodwill	-	$0	$-225,000	$-1,520,000
Otherunder Preferred Stock Dividend	-	$0	$16,000	$288,000
Restructuring And Mergern Acquisition	-	$0	$225,000	$410,000
Gain On Sale Of Security	-	-	-	$-1,110,000
Other Special Charges	-	-	-	-

Fetched: 2026-06-20

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$129,380,000	$7,492,000	$11,313,000	$12,479,000
Total Assets	$134,344,000	$10,880,000	$14,052,000	$15,763,000
Total Non Current Assets	$123,000	$386,000	$724,000	$1,030,000
Other Non Current Assets	$123,000	$299,000	$38,000	$38,000
Current Assets	$134,221,000	$10,494,000	$13,328,000	$14,733,000
Current Deferred Assets	$0	$75,000	$112,000	$114,000
Prepaid Assets	$572,000	$574,000	$636,000	$798,000
Receivables	$264,000	$24,000	$148,000	$1,438,000
Other Receivables	$264,000	$24,000	$148,000	$1,438,000
Cash Cash Equivalents And Short Term Investments	$133,385,000	$9,821,000	$12,432,000	$12,383,000
Cash And Cash Equivalents	$133,385,000	$9,821,000	$12,432,000	$12,383,000
Non Current Prepaid Assets	-	$273,000	$478,000	$682,000
Non Current Deferred Assets	-	-	-	-
Accounts Receivable	-	-	-	-
Debt
Total Debt	$71,000	$169,000	$369,000	$404,000
Current Debt And Capital Lease Obligation	$71,000	$169,000	$279,000	$193,000
Current Debt	$71,000	$79,000	$158,000	$88,000
Other Current Borrowings	$71,000	$79,000	$158,000	$88,000
Long Term Debt And Capital Lease Obligation	-	$0	$90,000	$211,000
Liabilities
Total Liabilities Net Minority Interest	$4,964,000	$3,388,000	$2,739,000	$3,284,000
Total Non Current Liabilities Net Minority Interest	$328,000	$152,000	$153,000	$272,000
Other Non Current Liabilities	$266,000	$150,000	$61,000	$61,000
Derivative Product Liabilities	$62,000	$2,000	$2,000	$61,000
Current Liabilities	$4,636,000	$3,236,000	$2,586,000	$3,012,000
Other Current Liabilities	$313,000	-	-	-
Payables And Accrued Expenses	$2,954,000	$2,345,000	$1,398,000	$2,153,000
Payables	$930,000	$1,214,000	$844,000	$1,828,000
Accounts Payable	$930,000	$1,214,000	$844,000	$1,828,000
Equity
Common Stock Equity	$129,378,000	$7,490,000	$11,311,000	$12,477,000
Preferred Stock Equity	$2,000	$2,000	$2,000	$2,000
Total Equity Gross Minority Interest	$129,380,000	$7,492,000	$11,313,000	$12,479,000
Stockholders Equity	$129,380,000	$7,492,000	$11,313,000	$12,479,000
Retained Earnings	$-152,725,000	$-135,944,000	$-121,506,000	$-109,190,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$159,644,017	$2,968,646	$818,059	$396,287
Share Issued	$159,644,017	$2,968,646	$818,059	$396,287
Tangible Book Value	$129,378,000	$7,490,000	$11,311,000	$12,477,000
Invested Capital	$129,449,000	$7,569,000	$11,469,000	$12,565,000
Working Capital	$129,585,000	$7,258,000	$10,742,000	$11,721,000
Capital Lease Obligations	$0	$90,000	$211,000	$316,000
Total Capitalization	$129,380,000	$7,492,000	$11,313,000	$12,479,000
Additional Paid In Capital	$280,509,000	$143,407,000	$132,811,000	$121,637,000
Capital Stock	$1,596,000	$29,000	$8,000	$32,000
Common Stock	$1,594,000	$27,000	$6,000	$30,000
Preferred Stock	$2,000	$2,000	$2,000	$2,000
Current Capital Lease Obligation	$0	$90,000	$121,000	$105,000
Pensionand Other Post Retirement Benefit Plans Current	$1,298,000	$722,000	$909,000	$666,000
Current Accrued Expenses	$2,024,000	$1,131,000	$554,000	$325,000
Net PPE	$0	$87,000	$208,000	$310,000
Gross PPE	$0	$87,000	$208,000	$310,000
Buildings And Improvements	$0	$84,000	$198,000	$300,000
Properties	$0	$0	$0	$0
Long Term Capital Lease Obligation	-	$0	$90,000	$211,000
Other Properties	-	$3,000	$10,000	$10,000
Preferred Shares Number	-	-	$200,000	$200,000
Machinery Furniture Equipment	-	-	-	-

Fetched: 2026-06-20

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-10,847,000	$-12,193,000	$-11,137,000	$-13,370,000
Operating Activities
Operating Cash Flow	$-10,847,000	$-12,193,000	$-11,133,000	$-13,360,000
Cash Flow From Continuing Operating Activities	$-10,847,000	$-12,193,000	$-11,133,000	$-13,360,000
Operating Gains Losses	$349,000	$-50,000	$145,000	$-1,316,000
Investing Activities
Investing Cash Flow	-	$0	$-4,000	$-10,000
Cash Flow From Continuing Investing Activities	-	$0	$-4,000	$-10,000
Capital Expenditure	-	-	$-4,000	$-10,000
Financing Activities
Issuance Of Capital Stock	$128,219,000	$8,435,000	$9,419,000	$14,401,000
Financing Cash Flow	$134,440,000	$9,582,000	$11,186,000	$15,258,000
Cash Flow From Continuing Financing Activities	$134,440,000	$9,582,000	$11,186,000	$15,258,000
Net Other Financing Charges	$-1,113,000	$-944,000	$-617,000	$-627,000
Net Common Stock Issuance	$128,219,000	$8,435,000	$9,419,000	$14,401,000
Common Stock Issuance	$128,219,000	$8,435,000	$9,419,000	$14,401,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Repayment Of Debt	$-320,000	$-426,000	$-391,000	$-790,000
Interest Paid Supplemental Data	$10,000	$14,000	$14,000	$12,000
End Cash Position	$133,440,000	$9,847,000	$12,458,000	$12,409,000
Beginning Cash Position	$9,847,000	$12,458,000	$12,409,000	$10,521,000
Changes In Cash	$123,593,000	$-2,611,000	$49,000	$1,888,000
Proceeds From Stock Option Exercised	$7,654,000	$2,517,000	$2,775,000	$2,274,000
Net Issuance Payments Of Debt	$-320,000	$-426,000	$-391,000	$-790,000
Net Short Term Debt Issuance	$-320,000	$-426,000	$-391,000	$-790,000
Short Term Debt Payments	$-320,000	$-426,000	$-391,000	$-790,000
Change In Working Capital	$1,639,000	$1,391,000	$400,000	$1,250,000
Change In Other Current Liabilities	$-90,000	$-121,000	$-105,000	$-151,000
Change In Payables And Accrued Expense	$1,200,000	$762,000	$-200,000	$399,000
Change In Accrued Expense	$576,000	$-56,000	$292,000	-
Change In Payable	$624,000	$818,000	$-492,000	-
Change In Account Payable	$624,000	$818,000	$-492,000	-
Change In Prepaid Assets	$529,000	$750,000	$705,000	$1,027,000
Other Non Cash Items	$-87,000	$249,000	$-6,000	$-69,000
Stock Based Compensation	$3,955,000	$652,000	$624,000	$1,032,000
Asset Impairment Charge	$75,000	$0	-	-
Depreciation Amortization Depletion	$3,000	$3,000	$4,000	$3,000
Depreciation And Amortization	$3,000	$3,000	$4,000	$3,000
Depreciation	$3,000	$3,000	$4,000	$3,000
Gain Loss On Investment Securities	$349,000	$-54,000	$145,000	$-1,316,000
Gain Loss On Sale Of PPE	$0	$4,000	$0	-
Net Income From Continuing Operations	$-16,781,000	$-14,438,000	$-12,300,000	$-14,260,000
Net PPE Purchase And Sale	-	$0	$-4,000	$-10,000
Purchase Of PPE	-	$0	$-4,000	$-10,000
Change In Other Working Capital	-	-	$292,000	$-25,000
Issuance Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$-790,000
Long Term Debt Payments	-	-	-	$-790,000
Long Term Debt Issuance	-	-	-	$0
Net Business Purchase And Sale	-	-	-	$0
Sale Of Business	-	-	-	$0
Purchase Of Business	-	-	-	$0
Change In Receivables	-	-	-	$0

Fetched: 2026-06-20